PHOENIX Study Meets Enrollment, Atogepant and Ubrogepant Safe, ABATE Trial Highlights Targeted Response of Alzheimer Vaccine
Neurology News Network for the week ending February 11, 2023. [WATCH TIME: 3 minutes]
NeurologyLive® Friday 5 — February 10, 2023
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 10, 2023.
This Week on NeurologyLive® — February 6, 2023
Here's some of what is coming soon to NeurologyLive® this week.
New Diagnostic Criteria Established for MOGAD, FDA Approves Proclaim XR SCS System, Clinical Hold on IKT-148009 Lifted
Neurology News Network for the week ending February 4, 2023. [WATCH TIME: 4 minutes]
NeurologyLive® Friday 5 — February 3, 2023
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 3, 2023.
This Week on NeurologyLive® — January 29, 2023
Evoke SCS System Shows Positive 36-Month Results, FDA Lifts Hold on FORTIS, Complete Response Letter Issued for Donanemab
Neurology News Network for the week ending January 28, 2023. [WATCH TIME: 4 minutes]
NeurologyLive® Friday 5 — January 27, 2023
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 27, 2023.
This Week on NeurologyLive® — January 23, 2023
COVID-19 Vaccine and Potential Stroke Concern, Associations Between AEDs and Incident Parkinson, FDA Accepts sBLA for DaxibolinumtoxinA
Neurology News Network for the week ending January 21, 2022. [WATCH TIME: 3 minutes]
NeurologyLive® Friday 5 — January 20, 2023
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 20, 2023.
This Week on NeurologyLive® — January 16, 2023
24-Hour Levodopa Solution Improves ON Time, Eisai Submits sBLA for Traditional Approval of Lecanemab, Rare Case of Seronegative NMOSD Identified
Neurology News Network for the week ending January 14, 2022. [WATCH TIME: 4 minutes]
NeurologyLive® Friday 5 — January 13, 2023
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 13, 2023.
This Week on NeurologyLive® — January 9, 2023
Pimavanserin's Positive Impact on Mortality, Concerns Raised Over Lecanemab Patient Death, FDA Clears Zoom RDL Access System
Neurology News Network for the week ending January 7, 2022. [WATCH TIME: 4 minutes]
NeurologyLive® Friday 5 — January 6, 2023
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 6, 2023.
This Week on NeurologyLive® — January 2, 2023
NeurologyLive® Year in Review 2022: Most-Watched Sleep Disorder Expert Interviews
These were the most-watched interviews with experts in sleep disorders that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.
FDA Approves Essential Tremor Treatment, Alzheimer's Association Files Request to CMS, Duchenne Therapy ENTR-601-44 Placed on Hold
Neurology News Network for the week ending December 31, 2022. [WATCH TIME: 3 minutes]
NeurologyLive® Year in Review 2022: Most-Watched Stroke and Brain Injury Expert Interviews
These were the most-watched interviews with experts in stroke and brain injury that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.
NeurologyLive® Year in Review 2022: Top Stories in Multiple Sclerosis
As part of NeurologyLive®'s Year in Review, take a look at our most-read news in multiple sclerosis in 2022.
NeurologyLive® Year in Review 2022: Most-Listened Mind Moments® Episodes
In 2022, these episodes of the Mind Moments® podcast got the most attention from listeners, with this list brought to you as part of NeurologyLive®'s Year in Review.
NeurologyLive® Year in Review 2022: Most-Watched Neuromuscular Disorder Expert Interviews
These were the most-watched interviews with experts in neuromuscular disorders that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.
NeurologyLive® Year in Review 2022: Top Stories in Movement Disorders
As part of NeurologyLive®'s Year in Review, take a look at the top most-read news in movement disorders in 2022.
NeurologyLive® Year in Review 2022: Most-Read FDA Approval Stories
These were the most-read FDA approval stories that were part of our coverage in 2022, brought to you as part of NeurologyLive®'s Year in Review.
NeurologyLive® Year in Review 2022: Most-Watched Movement Disorder Expert Interviews
These were the most-watched interviews with experts in movement disorders that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.
NeurologyLive® Year in Review 2022: Most-Watched Multiple Sclerosis Expert Interviews
These were the most-watched interviews with experts in multiple sclerosis that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.
NeurologyLive® Year in Review 2022: Top Stories in Stroke and Cerebrovascular Disease
As part of NeurologyLive®'s Year in Review, take a look at our most-read news in stroke and cerebrovascular disease in 2022.
NeurologyLive® Year in Review 2022: Most-Watched Video Series Episodes
These were the most-watched episodes of 2022 from our various video series, brought to you as part of NeurologyLive®'s Year in Review.